Browsing by Author Cebon, Jonathan Simon

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 10 of 10
Issue DateTitleAuthor(s)Citation
2013BRAF/NRAS Wild-Type Melanomas Have a High Mutation Load Correlating with Histologic and Molecular Signatures of UV DamageKakavand, Hojabr; Mann, Graham; Scolyer, Richard; Thompson, John; Behren, Andreas; Cebon, Jonathan Simon; Dobrovic, Alexander; Kelly, John; Li, Jason; Mar, Victoria; McArthur, Grant A.; McLean, Catriona; Papenfuss, Anthony Troy; Tothill, Richard W.; Wolfe, Rory; Wong, Stephen; Central Clinical School: Melonoma & Skin Cancer Res. Inst.; Western Clinical School: Westmead Millennium Institute; Central Clinical School: Pathology; Central Clinical School: SurgeryBRAF/NRAS Wild-Type Melanomas Have a High Mutation Load Correlating with Histologic and Molecular Signatures of UV Damage, Clinical Cancer Research, vol.19, 17, 2013,pp 4589-4598
2011Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rateMurali, Rajmohan; Scolyer, Richard; Thompson, John; Azad, Arun; Browning, Judy; Cebon, Jonathan Simon; Davis, Ian; Deb, Siddhartha; MacGregor, Duncan P.; Pollara, Gabriele; Svobodova, Suzanne J.; Central Clinical School: Pathology; Central Clinical School: Pathology; Central Clinical School: SurgeryCancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate, European Journal of Cancer, vol.47, 3, 2011,pp 460-469
2014Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitorKefford, Richard (Rick); Long, Georgina; Cebon, Jonathan Simon; et al, Various; Flaherty, Keith; Hamid, Omid; Infante, Jeffrey; Johnson, Douglas B; Kim, Kevin; McWilliams, Robert; Schuchter, Lynn; Sharfman, William; Weber, Jeffrey; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer CentreCombined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor, Journal of Clinical Oncology, vol.32, 33, 2014,pp 3697-3704
2017Efficacy of anti-PD-1 therapy in patients with melanoma brain metastasesCarlino, Matteo; Drummond, Martin; Guminski, Alexander; Kefford, Richard (Rick); Lo, Serigne; Long, Georgina; Menzies, Alexander Maxwel; Park, John; Rai, Rajat; Andrews, Miles C; Cebon, Jonathan Simon; Haydon, Andrew; Klein, O; McArthur, Grant A.; Mendis, S; Parakh, S; Rowe, Catherine; Wong, Annie; Xu, Wen; Western Clinical School: Medicine (Westmead); School of Public Health: Public Health; Northern Clinical School: Medicine; Western Clinical School: Medicine (Westmead); The George Institute for Global Health; Northern Clinical School: Medicine; Northern Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: MedicineEfficacy of anti-PD-1 therapy in patients with melanoma brain metastases, British Journal of Cancer, vol.116, 12, 2017,pp 1558-1563
2012Expression of cancer-testis antigens (MAGE-A1, MAGE-A3/6, MAGE-A4, MAGE-C1 and NY-ESO-1) in primary human uveal and conjunctival melanomaConway, Robert (Max); Madigan, Michele; Walsh-Conway, Natalie; Browning, Judy; Cebon, Jonathan Simon; Errington, J; Freyer, C; Central Clinical School: Clinical Ophthal & Eye Health; Central Clinical School: Clinical Ophthal & Eye Health; Central Clinical School: Clinical Ophthal & Eye HealthExpression of cancer-testis antigens (MAGE-A1, MAGE-A3/6, MAGE-A4, MAGE-C1 and NY-ESO-1) in primary human uveal and conjunctival melanoma, British Journal of Ophthalmology (BJO Online), vol.96, 3, 2012,pp 451-458
2017Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 ImmunotherapyLong, Georgina; Andtbacka, R; Cebon, Jonathan Simon; Dummer, R; et al, Various; Malvehy, Josep; Michielin, Olivier; Olszanski, Anthony; Puzanov, Igor; Ribas, Antoni; VanderWalde, Ari; Northern Clinical School: MedicineOncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy, Cell, vol.170, 6, 2017,pp 1109-1119
2016Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With TrametinibKefford, Richard (Rick); Long, Georgina; Cebon, Jonathan Simon; Daud, Adil; et al, .; Gonzalez, Rene; Hamid, Omid; Infante, Jeffrey; Kim, Kevin B; Schuchter, Lynn; Sosman, Jeffrey; Weber, Jeffrey; Western Clinical School: Westmead Institute for Medical Res; Central Clinical School: The Sydney Cancer CentreOverall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib, Journal of Clinical Oncology, vol.34, 8, 2016,pp 871-878
2016Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With TrametinibKefford, Richard (Rick); Long, Georgina; Cebon, Jonathan Simon; Daud, Adil; et al, .; Gonzalez, Rene; Hamid, Omid; Infante, Jeffrey; Kim, Kevin B; Schuchter, Lynn; Sosman, Jeffrey; Weber, Jeffrey; Western Clinical School: Westmead Institute for Medical Res; Central Clinical School: The Sydney Cancer CentreOverall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib, Journal of Clinical Oncology, vol.34, 8, 2016,pp 871-878
2017Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trialCarlino, Matteo; Guminski, Alexander; Kong, Benjamin; Lomax, Anna; Long, Georgina; McNeil, Catriona; Menzies, Alexander Maxwel; Atkins, Michael B; Atkinson, Victoria; Cebon, Jonathan Simon; Ebbinghaus, Scot; Fitzharris, Bernie; Hill, A; Hodi, F. Stephen; Hwu, Wen-Jen; Ibrahim, Nageatte; Islam, Mohammed; Jameson, Michael B; Kefford, Richard; Ribas, Antoni; Shu, Xinxin; Srivastava, Archana; Tamjid, Babak; Thompson, John; Westmead Clinical School: Medicine; Northern Clinical School: Medicine; Central Clinical School: Office; Central Clinical School: Melonoma & Skin Cancer Res. Inst.; Northern Clinical School: Medicine; Central Clinical School: Medicine; Northern Clinical School: MedicineStandard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial, The Lancet Oncology, vol.18, 9, 2017,pp 1202-1210
2017Whole-genome landscapes of major melanoma subtypesBurke, Hazel; Dagg, Rebecca; De Paoli-Iseppi, Ricardo; Hayward, Nicholas; Hersey, Peter; Jakrot, Valerie; Kakavand, Hojabr; Kefford, Richard (Rick); Lau, Loretta; Long, Georgina; Mann, Graham; Pickett, Hilda; Pupo, Gulietta; Saw, Robyn; Schramm, Sarah-Jane; Scolyer, Richard; Shang, Ping; Spillane, Andrew; Stretch, Jonathan; Tembe, Varsha; Thompson, John; Vilain, Ricardo; Wilmott, James; Yang, Jean Yee Hwa; Alexandrov, L; Behren, A; Cebon, Jonathan Simon; Dutton-Regester, K; Field, M; Fitzgerald, A; Grimmond, Sean Michael; Holmes, O; Johansson, P; Kazakoff, S; Leonard, Conrad; Lopez-Bigas, Nuria; Mularoni, L; Newell, F; Nones, Katia; Patch, Anne-Marie; Pearson, John V; Pritchard, Antonia L; Sabarinathan, R; Shackleton, Mark; Shang, C; Waddell, Nick; Waddell, Nicola; Wood, Scott; Xu, Qingying; Melanoma Foundation; School of Molecular Bioscience (SMB); Central Clinical School: Melonoma & Skin Cancer Res. Inst.; Medicine Faculty Office; Northern Clinical School: Surgery; Northern Clinical School: Medicine; Central Clinical School: Melonoma & Skin Cancer Res. Inst.; Western Clinical School: Medicine (Westmead); Childrens Hospital Westmead: Paediatrics & Child Health; Northern Clinical School: Medicine; Western Clinical School: Westmead Institute for Medical Res; Childrens Medical Research Institute (CMRI); Western Clinical School: Medicine (Westmead); Central Clinical School: Surgery; Western Clinical School: Medicine (Westmead); Central Clinical School: Pathology; Northern Clinical School: Kolling Institute; Northern Clinical School: Surgery; Central Clinical School: Surgery; Western Clinical School: Westmead Institute for Medical Res; Central Clinical School: Surgery; Central Clinical School: Pathology; Central Clinical School: Surgery; Mathematics & StatisticsWhole-genome landscapes of major melanoma subtypes, Nature, vol.545, 7653, 2017,pp 175-180